Searching On:

Disease:

Gene:

IDH1, all amino acid position R132 mutations

View:
Expand Collapse No disease selected  - General Description
Mass General Hospital Cancer Center treats patients with many cancer types. To learn more about the different cancer types that can be treated at the Cancer Center, please visit the Cancer Center website at the following page: http://www.massgeneral.org/cancer/services/
Expand Collapse IDH1  - General Description The IDH1 gene encodes an enzyme called isocitrate dehydrogenase 1, found in the compartment of cells called the cytoplasm. This enzyme is normally involved in the transfer of energy from one molecule to another during certain biochemical reactions within the cell. Mutations involving the IDH1 gene have been found in various cancers, including Acute Myeloid Leukemia (AML), intrahepatic bile duct cancers (Cholangiomas), Chondrosarcomas, and specific brain tumors (gliomas and glioblastomas). These alterations cause the amino acid (protein building block) arginine to be replaced by a different amino acid at a key position in the long chain of amino acids that make up this protein. The change in amino acid sequence alters the structure of the protein, resulting in loss of its normal function. Instead of its' normal metabolic product, the mutated IDH1 produces a new metabolite, R (-)-2-hydroxyglutarate, also called 2-HG. 2HG inhibits Tet and KGM enzymes, which alter the organization of DNA and disrupt normal gene expression patterns. These changes contribute directly to the development of cancer. Tumor mutation profiling performed clinically at the MGH Cancer Center has identified the highest incidence of IDH1 mutations in brain tumors called gliomas (50-60%) and glioblastomas (~10%), cholangiocarcinomas (18-25%), chondrosarcomas, and Acute Myeloid Leukemia (5-10%). The IDH1 gene encodes for the metabolic enzyme isocitrate dehydrogenase 1. This enzyme is located in the cytoplasm and peroxisomes of cells, and normally functions to catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate, with the production of NADPH. Recurrent mutations in IDH1 occur primarily at codon 132. These mutations result in decreased normal enzymatic activity, while conferring neomorphic activity that produces the oncometabolite R(-)-2-hydroxyglutarate (2HG) as the end-product. Levels of 2HG can accumulate dramatically in IDH1-mutant tumors and this is thought to promote tumorigenesis by competitively inhibiting the activity of a number of dioxygenases. The net effect appears to involve the promotion of gene silencing through hypermethylation of DNA and histones, as well as the activation of the hypoxia-inducible factor signaling pathway. Tumor genotype testing performed clinically at the MGH Cancer Center has identified the highest incidence of IDH1 mutations in low-grade gliomas (50-60%), glioblastomas (~10%), cholangiocarcinomas (18-25%), chondrosarcomas, and acute myeloid leukemias (5-10%).
CLICK IMAGE FOR MORE INFORMATION
The IDH1 gene encodes an enzyme called isocitrate dehydrogenase 1, found in the compartment of cells called the cytoplasm. This enzyme is normally involved in the transfer of energy from one molecule to another during certain biochemical reactions within the cell.

Mutations involving the IDH1 gene have been found in various cancers, including Acute Myeloid Leukemia (AML), intrahepatic bile duct cancers (Cholangiomas), Chondrosarcomas, and specific brain tumors (gliomas and glioblastomas). These alterations cause the amino acid (protein building block) arginine to be replaced by a different amino acid at a key position in the long chain of amino acids that make up this protein. The change in amino acid sequence alters the structure of the protein, resulting in loss of its normal function. Instead of its' normal metabolic product, the mutated IDH1 produces a new metabolite, R (-)-2-hydroxyglutarate, also called 2-HG. 2HG inhibits Tet and KGM enzymes, which alter the organization of DNA and disrupt normal gene expression patterns. These changes contribute directly to the development of cancer.

Tumor mutation profiling performed clinically at the MGH Cancer Center has identified the highest incidence of IDH1 mutations in brain tumors called gliomas (50-60%) and glioblastomas (~10%), cholangiocarcinomas (18-25%), chondrosarcomas, and Acute Myeloid Leukemia (5-10%).
The IDH1 gene encodes for the metabolic enzyme isocitrate dehydrogenase 1. This enzyme is located in the cytoplasm and peroxisomes of cells, and normally functions to catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate, with the production of NADPH.

Recurrent mutations in IDH1 occur primarily at codon 132. These mutations result in decreased normal enzymatic activity, while conferring neomorphic activity that produces the oncometabolite R(-)-2-hydroxyglutarate (2HG) as the end-product. Levels of 2HG can accumulate dramatically in IDH1-mutant tumors and this is thought to promote tumorigenesis by competitively inhibiting the activity of a number of dioxygenases. The net effect appears to involve the promotion of gene silencing through hypermethylation of DNA and histones, as well as the activation of the hypoxia-inducible factor signaling pathway.

Tumor genotype testing performed clinically at the MGH Cancer Center has identified the highest incidence of IDH1 mutations in low-grade gliomas (50-60%), glioblastomas (~10%), cholangiocarcinomas (18-25%), chondrosarcomas, and acute myeloid leukemias (5-10%).
PubMed ID's
22234630, 22180306
Expand Collapse all amino acid position R132 mutations  in IDH1
Preclinical Research has demonstrated that some cancers harbor mutations in IDH1 gene that result in altered amino acids in position 132 of the protein. These include R132C (c.394 C>T); R132G (c.394 C>G); R132H (c.395 G>A); R132L (c.395 G>T); and R132S (c.394 C>A); All result in altered activity in the enzyme, producing 2-HG instead of the metabolic product produced by the normal enzyme.
Preclinical Research has demonstrated that some cancers harbor mutations in IDH1 gene that result in altered amino acids in position 132 of the protein. These include R132C (c.394 C>T); R132G (c.394 C>G); R132H (c.395 G>A); R132L (c.395 G>T); and R132S (c.394 C>A); All result in altered activity in the enzyme, producing 2-HG instead of the metabolic product produced by the normal enzyme.

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (G) - Gene, (M) - Mutation
Trial Status: Showing all 7 results Per Page:
Protocol # Title Location Status Match
NCT03515512 IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation MGH Open GM
NCT03173248 Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation MGH Open GM
NCT03343197 Study of AG-120 and AG-881 in Subjects With Low Grade Glioma Study of AG-120 and AG-881 in Subjects With Low Grade Glioma MGH Open GM
NCT02968940 Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma MGH Open G
NCT02977780 INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) MGH Open G
NCT03180502 Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma MGH Open G
NCT02989857 Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) MGH Open G
MGH has many open clinical trials for other cancers not shown on the Targeted Cancer Care website. They can be found on the MassGeneral.org clinical trials search page.

Additional clinical trials may be applicable to your search criteria, but they may not be available at MGH. These clinical trials can typically be found by searching the clinicaltrials.gov website.
Trial Status: Showing all 7 results Per Page:

Share with your Physican

Print information for your Physician.

Print information